Association between intrarenal arterial resistance and diastolic dysfunction in type 2 diabetes

MacIsaac, Richard J.; Thomas, Merlin C.; Panagiotopoulos, Sianna; Smith, Trudy J.; Hao, Huming; Matthews, D. Geoffrey; Jerums, George; Burrell, Louise M.; Srivastava, Piyush M.
January 2008
Cardiovascular Diabetology;2008, Vol. 7, p1
Academic Journal
Background: In comparison to the well established changes in compliance that occur at the large vessel level in diabetes, much less is known about the changes in compliance of the cardiovascular system at the end-organ level. The aim of this study was therefore to examine whether there was a correlation between resistance of the intrarenal arteries of the kidney and compliance of the left ventricle, as estimated by measurements of diastolic function, in subjects with type 2 diabetes. Methods: We studied 167 unselected clinic patients with type 2 diabetes with a kidney duplex scan to estimate intrarenal vascular resistance, i.e. the resistance index (RI = peak systolic velocityminimum diastolic velocity/peak systolic velocity) and a transthoracic echocardiogram (TTE) employing tissue doppler studies to document diastolic and systolic ventricular function. Results: Renal RI was significantly higher in subjects with diastolic dysfunction (0.72 � 0.05) when compared with those who had a normal TTE examination (0.66 � 0.06, p < 0.01). Renal RI values were correlated with markers of diastolic dysfunction including the E/Vp ratio (r = 0.41, p < 0.001), left atrial area (r = 0.36, p < 0.001), the E/A ratio (r = 0.36, p < 0.001) and the E/E' ratio (r = 0.31, p < 0.001). These associations were independent of systolic function, hypertension, the presence and severity of chronic kidney disease, the use of renin-angiotensin inhibitors and other potentially confounding variables. Conclusion: Increasing vascular resistance of the intrarenal arteries was associated with markers of diastolic dysfunction in subjects with type 2 diabetes. These findings are consistent with the hypothesis that vascular and cardiac stiffening in diabetes are manifestations of common pathophysiological mechanisms.


Related Articles

  • Fibroelastoma papilar cardiaco. Una inusual presentaci�n. Rodr�guez-Ortega, Manuel Fernando; Jacobo-Valdivieso, El�as Jos�; Flores-Calder�n, Octavio; Garc�a-Orteg�n, Mar�a del Sol; Le�n-Hern�ndez, Gisela; Luna-Saucedo, Mar�a Delfina // Cirugia y Cirujanos;jul/ago2007, Vol. 75 Issue 4, p293 

    Background: Papillary fibroelastoma is a rare benign tumor characterized morphologically since first being described in 1976. Nevertheless, this tumor can be presented with a variety of clinical manifestations, making diagnosis challenging for the physician. There are no gender or age...

  • Improvement of Left Ventricular Diastolics in Prediabetic Stage of A Type II Diabetic Rat Model After Troglitazone Treatment. Li Yao; Mizushige, Katsufumi; Noma, Takahisa; Murakami, Kazushi; Ohmori, Koji; Matsuo, Hirohide // Angiology;Jan2001, Vol. 52 Issue 1, p53 

    Reports on a study on the improvement of left ventricular diastolic dynamics in prediabetic stage of a Type II diabetic rat model after troglitazone treatment. Hypoglycemic effects of troglitazone in insulin-resistant animal models; Performance of echocardiography; Finding that troglitazone...

  • Sex and Type 2 Diabetes: Obesity-Independent Effects on Left Ventricular Substrate Metabolism and Relaxation in Humans. Peterson, Linda R.; Saeed, Ibrahim M.; McGill, Janet B.; Herrero, Pilar; Schechtman, Kenneth B.; Gunawardena, Ratnasiri; Recklein, Carol L.; Coggan, Andrew R.; DeMoss, Amanda J.; Dence, Carmen S.; Gropler, Robert J. // Obesity (19307381);Apr2012, Vol. 20 Issue 4, p802 

    Patients with type 2 diabetes (T2DM), particularly women, are at risk for heart failure. Myocardial substrate metabolism derangements contribute to cardiac dysfunction in diabetic animal models. The purpose of this study was to determine the effects of diabetes and sex on myocardial metabolism...

  • Current evidence for carotid endarterectomy and carotid artery stenting. Roffi, Marco // Heart;Apr2010, Vol. 96 Issue 8, p636 

    The article details the respective roles of carotid endarterectomy (CEA) and carotid artery stenting (CAS) in patients with carotid artery stenosis. It relates the randomised trials of CEA versus medical treatment. It discusses the randomised clinical trials of CEA and CAS. It presents a...

  • The association between extracoronary calcification and coronary artery disease in patients with type 2 diabetes mellitus. Farrag, Azza; Bakhoum, Sameh; Salem, Mohammed; El-Faramawy, Amr; Gergis, Emmanuel // Heart & Vessels;Jan2013, Vol. 28 Issue 1, p12 

    Cardiovascular complications are the major cause of diabetes-associated morbidity and mortality. However, not all patients with diabetes are at increased risk for cardiovascular disease (CVD). Coronary artery calcification was found to be a powerful predictor of coronary artery disease (CAD)....

  • Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: A comparative study Symeonides, Phivos; Koulouris, Spyridon; Vratsista, Ekaterini; Triantafyllou, Konstantinos; Ioannidis, Georgios; Thalassinos, Nikolaos; Katritsis, Demosthenes // European Journal of Echocardiography;Dec2007, Vol. 8 Issue 6, p480 

    Abstract: Aims: We tested the hypothesis that renin–angiotensin system inhibition could reverse left ventricular diastolic dysfunction in patients with type 2 diabetes. Methods and results: Forty asymptomatic patients with type 2 diabetes were recruited in this double-blind cross-over...

  • 2008 - Intensive glucose control increased mortality and did not prevent cardiovascular events in type 2 diabetes. Montori, Victor M.; Malaga, German // ACP Journal Club;9/16/2008, Vol. 149 Issue 3, p5 

    The article provides an answer to the question whether intensive glucose control prevents cardiovascular events more than standard glucose control in patients suffering from type 2 diabetes and cardiovascular disease or risk factors.

  • Reducing cardiovascular risk in patients with type 2 diabetes: Management of dyslipidemia. Hilleman, Daniel E. // Formulary;Aug2003, Vol. 38 Issue 8, p478 

    Focuses on reducing cardiovascular risk in patients with type 2 diabetes. Characteristics of type 2 diabetes; Treatment goals for dyslipidemia in diabetes; Alleged association between the excess cardiovascular risk in patients with diabetes and glycemic control; Drugs affecting lipoprotein...

  • Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. Gæde, Peter; Vedel, Pernille; Larsen, Nicolai; Jensen, Gunnar V.H.; Parving, Hans-Henrik; Pedersen, Oluf // New England Journal of Medicine;1/30/2003, Vol. 348 Issue 5, p383 

    Background: Cardiovascular morbidity is a major burden in patients with type 2 diabetes. In the Steno-2 Study, we compared the effect of a targeted, intensified, multifactorial intervention with that of conventional treatment on modifiable risk factors for cardiovascular disease in patients with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics